Extended biopsy based criteria incorporating cumulative cancer length for predicting clinically insignificant prostate cancer

BJU International

Volumn 110, Issue 11 B, 2012, Pages

  Komai, Yoshinobu ^a   Kawakami, Satoru ^a   Numao, Noboru ^a   Fujii, Yasuhisa ^a   Saito, Kazutaka ^a   Kubo, Yuichi ^b   Koga, Fumitaka ^a   Kumagai, Jiro ^a   Yamamoto, Shinya ^b   Yonese, Junji ^b   Ishikawa, Yuichi ^b   Fukui, Iwao ^b   Kihara, Kazunori ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Biopsy; Extended; Insignificant cancer; Prostate

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER STAGING; COHORT ANALYSIS; CUMULATIVE CANCER LENGTH; GLEASON SCORE; HUMAN; HUMAN TISSUE; INSIGNIFICANT PROSTATE CANCER; MAJOR CLINICAL STUDY; MALE; ONCOLOGICAL PARAMETERS; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RECEIVER OPERATING CHARACTERISTIC; CANCER GRADING; COMPARATIVE STUDY; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; NEEDLE BIOPSY; PATHOLOGY; PATIENT SELECTION; PROGNOSIS; PROSTATE TUMOR;

AGED; BIOPSY, NEEDLE; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PATIENT SELECTION; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; ROC CURVE;

MLCS; MLOWN;

EID: 84876426635     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11272.x     Document Type: Article

References (32)

1. Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009 ; 360 : 1320-8
2. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 2007 ; 178 : S14-9
3. Carter HB, Sauvageot J, Walsh PC, Epstein JI. Prospective evaluation of men with stage T1C adenocarcinoma of the prostate. J Urol 1997 ; 157 : 2206-9
4. Kattan MW, Eastham JA, Wheeler TM et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003 ; 170 : 1792-7
5. Anast JW, Andriole GL, Bismar TA, Yan Y, Humphrey PA. Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population? Urology 2004 ; 64 : 544-50
6. Steyerberg EW, Roobol MJ, Kattan MW, van der Kwast TH, de Koning HJ, Schroder FH. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 2007 ; 177 : 107-12
7. Chun FK, Haese A, Ahyai SA et al. Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. C ancer 2008 ; 113 : 701-9
8. Epstein JI, Chan DW, Sokoll LJ et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 1998 ; 160 : 2407-11
9. Lee MC, Dong F, Stephenson AJ, Jones JS, Magi-Galluzzi C, Klein EA. The Epstein criteria predict for organconfined but not insignificant disease and a high likelihood of cure at radical prostatectomy. Eur Urol 2010 ; 58 : 90-5
10. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994 ; 271 : 368-74
11. Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 2006 ; 175 : 1605-12
12. Scattoni V. Systematic prostate biopsies are more and more often becoming saturation biopsies. Eur Urol 2006 ; 50 : 202-4
13. Jones JS. Saturation biopsy for detecting and characterizing prostate cancer. BJU Int 2007 ; 99 : 1340-4
14. Kawakami S, Hyochi N, Yonese J et al. Three-dimensional combination of transrectal and transperineal biopsies for efficient detection of stage T1c prostate cancer. Int J Clin Oncol 2006 ; 11 : 127-32
15. Donovan J, Hamdy F, Neal D et al. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess 2003 ; 7 : 1-88
16. Nakanishi H, Wang X, Ochiai A et al. A nomogram for predicting low-volume/low-grade prostate cancer: a tool in selecting patients for active surveillance. Cancer 2007 ; 110 : 2441-7
17. Davis JW, Kim J, Ward JF et al. Radical prostatectomy findings in patients predicted to have low-volume/low-grade prostate cancer diagnosed by extended-core biopsies: an analysis of volume and zonal distribution of tumour foci. BJU Int 2010 ; 105 : 1386-91
18. Partin AW, Kattan MW, Subong EN et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997 ; 277 : 1445-51
19. Pepe P, Galia A, Fraggetta F, Grasso G, Allegro R, Aragona F. Prediction by quantitative histology of pathological stage in prostate cancer. Eur J Surg Oncol 2005 ; 31 : 309-13
20. Numao N, Kawakami S, Yonese J et al. Three-dimensional 26-core biopsy-based patient selection criteria for nerves-paring radical prostatectomy. Int J Urol 2008 ; 15 : 1061-6
21. Yoshida S, Kawakami S, Numao N et al. Multi-sequence magnetic resonance imaging prior to prostate biopsy: correlation analysis using the pathological results and three-dimensional 26-core biopsy. Eur Urol Suppl 2009 ; 8 : 353
22. Kawakami S, Kihara K, Fujii Y, Masuda H, Kobayashi T, Kageyama Y. Transrectal ultrasound-guided transperineal 14-core systematic biopsy detects apico-anterior cancer foci of T1c prostate cancer. Int J Urol 2004 ; 11 : 613-8
23. Kawakami S, Okuno T, Yonese J et al. Optimal sampling sites for repeat prostate biopsy: a recursive partitioning analysis of three-dimensional 26-core systematic biopsy. Eur Urol 2007 ; 51 : 675-82
24. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol 2005 ; 29 : 1228-42
25. Yamamoto S, Yonese J, Kawakami S et al. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol 2007 ; 52 : 696-701
26. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010 ; 28 : 126-31
27. Goto Y, Ohori M, Arakawa A, Kattan MW, Wheeler TM, Scardino PT. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol 1996 ; 156 : 1059-63
28. Scattoni V, Maccagnano C, Zanni G et al. Is extended and saturation biopsy necessary? Int J Urol 2010 ; 17 : 432-47
29. Tosoian JJ, Loeb S, Kettermann A et al. Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol 2010 ; 183 : 534-8
30. Ficarra V, Novara G, Galfano A. Precursor isoform of prostate-specific antigen and human kallikrein 2: two new promising biomarkers for the unsolved challenge of early prostate cancer detection. Eur Urol 2009 ; 55 : 556-9
31. Eggener SE, Scardino PT, Walsh PC et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011 ; 185 : 869-75
32. Stephenson AJ, Kattan MW, Eastham JA et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009 ; 27 : 4300-5